Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 6/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12428492 | 0.89 | PRKCA (0.37) | PRKCAMMP12ESR1ESR2SCN9A | |
| SCHEMBL12428255 | 0.88 | PRKCA (0.40) | PRKCAMMP12ESR1ESR2SCN9A | |
| SCHEMBL10283614 | 0.86 | PRKCA (0.42) | L3MBTL1PRKCAMMP12KMT2AESR1 | |
| SCHEMBL12427985 | 0.86 | PRKCA (0.42) | L3MBTL1PRKCAMMP12KMT2AESR1 | |
| SCHEMBL792699 | 0.86 | PRKCA (0.41) | L3MBTL1PRKCAMMP12ALOX5ESR1 | |
| SCHEMBL10283489 | 0.86 | EGFR (0.44) | L3MBTL1PRKCAMMP12 | |
| SCHEMBL12427623 | 0.85 | PRKCA (0.43) | PRKCAMMP12MEN1KMT2ASCN9A | |
| SCHEMBL12429237 | 0.84 | PRKCA (0.41) | PRKCAMMP12ESR1ESR2SCN9A | |
| SCHEMBL12428343 | 0.84 | POLB (0.43) | PRKCAMMP12KMT2AESR1ESR2 | |
| SCHEMBL12427921 | 0.83 | PRKCA (0.42) | PRKCAMMP12ESR1ESR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | L3MBTL1 4435/4885PRKCA 2404/4885MMP12 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.